Prescription Drug Patent Licensing Act

Summary

Prescription Drug Patent Licensing Act - Requires that whenever the Federal Trade Commission, upon complaint made to it by a qualified applicant for a license under a drug patent, determines through an investigation and hearing that such application for license was not granted and that the price quoted to druggists by the patentee is more than 500 percent of the total cost of production, the Commission shall order such patentee to grant an unrestricted license to any qualified applicant to make, use, and sell such drug. States that the Commission may delay such order up to five years to provide a fair return on the patentee's invested capital. (Adds 35 U.S.C. 294)

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 1 August 1975

   Introduced

   Introduced in House

   Source: IntroReferral

2. 1 August 1975

   Introduced

   Introduced in House

   Source: IntroReferral

3. 1 August 1975

   Introduced

   Referred to House Committee on the Judiciary.

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Introduced in House

  summary · EN · 1 August 1975

  Open at official source

Sponsors

• Rep. Rosenthal, Benjamin S. [D-NY-8] · D · Sponsor
• Rep. Eilberg, Joshua [D-PA-4] · D · Cosponsor
• · hsju00 · Standing

Related records

• related to → Prescription Drug Patent Licensing Act